Virus-Like Particles as RSV Vaccine Candidate
Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection.
Candidates may have the most effective anti-viral and anti-inflammatory response.
Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus.
Efficient, tunable and stable production...
Inventor(s): Binh Ha, Larry Anderson, Elizabeth Wright
Trimeric Immunogen for HIV-1 Vaccination
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Antiretroviral therapy (ART) has dramatically prolonged...
Inventor(s): Rama Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
Glycoprotein Tetramer for Identifying Antigen-specific B Cells
ApplicationEctodomain of viral glycoprotein tetramers detects antigen-specific memory B Cells.Key BenefitsViral glycoprotein tetramers detect antigen-specific memory B cells in the peripheral blood and tissues.Hepatitis C virus E2 protein triggers immune response, which may yield an effective vaccine against hepatitis C virus.Market SummaryHepatitis...
Inventor(s): Arash Grakoui, Joseph Marcotrigiano
ApplicationStandalone smartphone app to increase vaccinations and improve vaccine knowledge for providers, pharmacists, and the general public.Key BenefitsProvides detailed information about a variety of vaccines and diseases. Sends out alerts and updates. Market SummaryVaccines prevent millions of cases of infectious diseases each year; however, many...
Inventor(s): Saad Omer, Robert Bednarczyk, Paula Frew, Walter Orenstein, Ines Gonzalez-Casanova, Neal Halsey, Daniel Salmon
Human Monoclonal Antibodies Against Ebola Virus
ApplicationAntibodies that bind and neutralize Ebola virus glycoprotein (GP) for use in vaccination or treatment of Ebola virus disease.Key BenefitsHigher binding affinity for Ebola virus GP than closest competitor.Can be used prophylactically or for treatment of Ebola virus disease.Market SummaryThe Ebola virus is an RNA virus with a membrane composed...
Inventor(s): Rafi Ahmed
Respiratory Syncytial Virus (RSV) A2 Expressing Firefly Luciferase
ApplicationRecombinant RSV strain expressing firefly luciferase and the F & G genes from clinical strain A2001/2-20 for research and development of vaccines.Key BenefitsF & G proteins included in this strain show different behavior than those of the typical A2 strain proteins.May be adapted in a variety of assays, enabling the identification of RSV...
Inventor(s): Martin Moore, Christopher Stobart
Helper Plasmids for Rescue of Respiratory Syncytial Virus
ApplicationPlasmids rescuing recombinant syncytial virus for RSV research and vaccine development.Key BenefitsAllow expression and recombination in vero cells.Optimized for human codon bios to increase expression in mammalian cells.Market SummaryRespiratory syncytial virus (RSV) is the major cause of acute lower respiratory tract infections in infants...
Inventor(s): Martin Moore
Plasmid for Respiratory Syncytial Virus (RSV) Vaccine Development & Research
ApplicationsBacterial artificial chromosome (BAC) plasmid containing the antigenomic sequence A2-BAG-BAF derived from multiple strains of RSV. Key BenefitsViral DNA is contained in a BAC, allowing for efficient mutagenesis and recombineering of viral DNA. BAC is stable and can be used for cloning in common bacteria types like E. coli.Provides powerful...
Inventor(s): Martin Moore, Anne Hotard (Lopez-Ona)
Recombinant Respiratory Syncytial Virus (RSV) Firefly Luciferase Reporter Strain
ApplicationModified recombinant syncytial virus (RSV) strain expressing a bioluminescent reporter protein for high throughput screening and vaccine development.Key BenefitsProvides a new high throughput screening tool for RSV vaccine development and drug discovery.Firefly luciferase based assays show better signal-to-noise than fluorescence-based assays.Market...
Inventor(s): Richard Plemper, Martin Moore
Membrane-anchored Fusokine as Vaccine Adjuvant to Prevent Viral Infection
ApplicationGIFT4 anchored to virus-like particles (VLPs) as a prophylactic vaccine adjuvant to prevent chronic viral infections including HIV, HBV, HPV and influenza.Key BenefitsGIFT4-containing VLPs induce higher antibody response than non-adjuvanted VLPs. Effectively induce strong mucosal immune response. Market SummaryMore than 36 million people...
Inventor(s): Baozhong Wang, Richard Compans, Jacques Galipeau, Jiusheng Deng